Status:
COMPLETED
Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults
Lead Sponsor:
Seneque SA
Collaborating Sponsors:
CEN Biotech
LGD
Conditions:
Healthy Volunteers
Eligibility:
All Genders
30-60 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the physiological and/or biological actions of nicotinamide mononucleotide (NMN-C) in healthy adults receiving a repeated-dose over the course of 28 days by st...
Eligibility Criteria
Inclusion
- Healthy volunteers should be
- Men between the ages of 30 and 60 years old
- With a BMI between 23 and 30 kg/m2
- With a weight \> or = 70kg
- Giving their free informed consent to the study
Exclusion
- May not be included in the study Volunteers with
- a history of allergy to vitamin B3 (niacin or nicotinamide)
- immunocompromised or suffering from a serious or progressive disease (cardiac, pulmonary, hepatic, renal, hematologic, neoplastic or infectious)
- with abnormal results on the screening bioassay (CBC, Transaminases (AST, ALT, GGT), Bilirubin, Creatinine, CPK, Ionogram, Blood glucose, Hba1c, Lipid profile)
- having donated blood in the month preceding inclusion,
- having consumed more than 2 glasses of alcohol per day,
- being under medication or taking food supplements,
- having reached the maximum compensation threshold for research involving the human being as provided for by the regulations or having participated in another biomedical research project that required blood samples in the previous month,
- involved in another clinical trial or being in the exclusion period of a previous clinical trial.
Key Trial Info
Start Date :
April 26 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 4 2022
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04862338
Start Date
April 26 2021
End Date
April 4 2022
Last Update
January 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biomed 21
Dijon, France, 21000